Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 926Neoplasms 609Breast Neoplasms 604Colorectal Neoplasms 457Neoplasm Metastasis 394Ovarian Neoplasms 328Melanoma 312Prostatic Neoplasms 311Lung Neoplasms 294Multiple Myeloma 290Recurrence 278Squamous Cell Carcinoma of Head and Neck 246Stomach Neoplasms 229Pancreatic Neoplasms 228Leukemia, Myeloid, Acute 220Triple Negative Breast Neoplasms 190Endometrial Neoplasms 190Carcinoma, Renal Cell 182Lymphoma, Non-Hodgkin 179Carcinoma, Hepatocellular 177Small Cell Lung Carcinoma 165Leukemia, Lymphocytic, Chronic, B-Cell 156Advanced Solid Tumors 154Lymphoma, Follicular 148Urinary Bladder Neoplasms 139Lymphoma, Large B-Cell, Diffuse 138Lymphoma 137Advanced Solid Tumor 137Uterine Cervical Neoplasms 134Head and Neck Neoplasms 134

Interventions

tremelimumab 1durvalumab 1Pemetrexed 1Gemcitabine 1Cisplatin 1Carboplatin 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Non Small Cell Lung Cancer NSCLC × 1 year × Clear all
NCT07169708 2026-05-20

A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL)

Ono Pharmaceutical Co., Ltd.

Recruiting
100 enrolled
Thoracic

Non Small Cell Lung Cancer NSCLC

NCT03164616 2026-03-13

POSEIDON

AstraZeneca

Phase 3 Active not recruiting
1,186 enrolled 26 charts 1 FDA
Thoracic

Non Small Cell Lung Cancer NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡